Remove 2018 Remove Omnicell Remove Pharmaceutical Companies
article thumbnail

Federal 340B Drug Pricing Program – An Industry Update and Mitigation Strategies Relative to Recent Challenges

Omnicell

Jeff Spencer Senior Director, 340B Sales and Account Management, Omnicell Since its inception 30 years ago, the 340B Drug Pricing Program has helped non-profit healthcare organizations expand services for their communities. Before 2018, the reimbursement level was Average Sales Price (ASP) was more than plus 6 percent.

article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

There was bipartisan support for the program at the hearing and support for measures such as requiring pharmaceutical companies to publish their prices in a password protected site on HRSA's website. 2018: The Centers for Medicare & Medicaid Services (CMS) imposed significant Medicare Part B reimbursement cuts to 340B hospitals.

article thumbnail

Congress Continues to Display Strong Bipartisan Support for the 340B Drug Pricing Program

Omnicell

percent of drug industry sales, based on 2018 data , the pharmaceutical industry continues to lobby against the program. Pharma’s Challenges to 340B During July and August, several large pharmaceutical companies challenged the operation of the 340B program. Yet, while 340B discounts equate to only about 1.4